Merck joins the cost-cutting bandwagon
With big pharma reaching for the tried and trusted remedy of mergers and acquiasitions, Merck has bid $44bn for rival Schering-Plough.
Big pharma is "reaching for a familiar old remedy", said Ian King in The Times: mergers and acquisitions. In January, Pfizer forked out $68bn for Wyeth. Rochehas upped its bid to buy out Genentech to $46.7bn. And now Merck has bid $44bn for rival Schering-Plough. Companies are scrambling to consolidate because blockbusters are coming off patent, generic competition is on the rise, and now Obama's health reforms "could blow a hole" in drugmakers' profits by forcing drug costs down.
Mergers are designed to beef up pipelines and save a fortune in costs. The big motivation for Merck is up to $25bn in potential cost cuts, said Robert Cyran on Breakingviews which works out as more than double the premium it's paying Schering-Plough. Merck will also double the number of late-stage drugs in its research portfolio and gain better access to overseas markets.
But putting big drug groups together hasn't bolstered the pace of drug discovery, said Richard Fletcher in The Daily Telegraph. Scientists are "irascible" and they tend to "mysteriously lose their productivity" when moved out of their comfort zone into a new lab. Merck's decision to join the cost-cutting bandwagon, said Lex in the FT, is the latest sign of the "broken drug discovery model".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
MRK: $22; 12m change -50%
SGP: $21; 12m change 2%
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Landlords ordered to make rental properties more energy efficient by 2030
The government has said rental properties must have a minimum EPC rating of C by 2030. We explain how much it will cost landlords to upgrade their buy-to-let portfolio
By Marc Shoffman Published
-
Primark owner Associated British Foods is an overlooked gem going cheap — should you buy shares?
Associated British Foods, the owner of Primark, is a family-owned business, which means it is passed over by the increasingly popular passive investment funds. That spells opportunity for private investors, says Jamie Ward.
By Jamie Ward Published